Chimeric Therapeutics (CHM) EGM 2026 summary

Opening remarks and agenda

• Meeting acknowledged traditional land custodians and was held in a hybrid format for broad shareholder participation.

• Voting was conducted by poll, with shareholders able to submit questions and votes online or in person.

• Directors, executive management, and company secretaries were introduced at the outset.

Specific resolutions to be voted on

• Ratification of 776 million first tranche placement shares and approval for 467 million attaching options.

• Approval for 690 million second tranche placement shares and 1 billion attaching options.

• Approval for 50 million adviser options.

• Approval for warrants and convertible notes, both interconditional.

• Approval for a one-for-100 share consolidation to address high share count and sub-cent share price.

Shareholder proposals specific to EGM

• Shareholders questioned the lack of a Share Purchase Plan (SPP) for retail investors and were told it was considered but participation rates have been low.

• Discussion on the impact of large shareholders and retail voting turnout.